Overview

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-820836 in healthy Japanese subjects and Japanese patients with depression.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Bristol-Myers Squibb
Criteria
Inclusion Criteria:

- Healthy Japanese subjects and Japanese patients with depression (Hamilton Rating Scale
for Depression (HAM-D) ≥ 14), ages 20 to 55 years.

Exclusion Criteria:

- Any significant acute or chronic medical illness.

- Non-compliance, or overall not suitable as determined by the investigator.

- History of, or current clinically significant psychiatric disorders or illnesses,
substance abuse or dependence.